Stock Analysis

China Isotope & Radiation Full Year 2024 Earnings: EPS: CN¥1.27 (vs CN¥1.16 in FY 2023)

SEHK:1763
Source: Shutterstock
Advertisement

China Isotope & Radiation (HKG:1763) Full Year 2024 Results

Key Financial Results

  • Revenue: CN¥7.57b (up 14% from FY 2023).
  • Net income: CN¥406.6m (up 9.6% from FY 2023).
  • Profit margin: 5.4% (down from 5.6% in FY 2023). The decrease in margin was driven by higher expenses.
  • EPS: CN¥1.27 (up from CN¥1.16 in FY 2023).
earnings-and-revenue-history
SEHK:1763 Earnings and Revenue History March 31st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

China Isotope & Radiation shares are up 2.3% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on China Isotope & Radiation's balance sheet health.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SEHK:1763

China Isotope & Radiation

Engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China.

Adequate balance sheet and slightly overvalued.

Advertisement